Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) presented Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), at IDWeek ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




